Physician profile
Ping Li
NPI 1619132651
$6,328.01
in general payments reported to CMS, 2019-2025
19 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $888 · 2020: $144 · 2021: $597 · 2022: $876 · 2023: $1,327 · 2024: $1,277 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,823.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,929.81 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Neuropace, INC. | $1,225.09 | 2019-2024 | |
| Sk Life Science, INC. | $1,159.08 | 2020-2025 | Xcopri |
| Ucb, INC. | $759.86 | 2021-2025 | Fintepla, Nayzilam, Briviact |
| Medtronic, INC. | $324.96 | 2023-2024 | Percept Pc Brainsense |
| Greenwich Biosciences, INC. | $193.59 | 2019-2020 | |
| Medtronic USA, INC. | $178.27 | 2019 | |
| Jazz Pharmaceuticals INC. | $158.27 | 2023-2025 | |
| Eisai INC. | $125.00 | 2019 | |
| Neurelis, INC. | $73.80 | 2020-2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $30.26 | 2024 | Motpoly Xr |
| Abbvie INC. | $29.87 | 2025 | |
| Biogen, INC. | $25.68 | 2025 | Spinraza |
| Supernus Pharmaceuticals, INC. | $25.48 | 2019-2022 | |
| Boston Scientific Corporation | $24.08 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $23.03 | 2024 | Dysport |
| Pfizer INC. | $21.17 | 2025 | |
| Acorda Therapeutics, INC | $20.71 | 2023 | Inbrija, Ampyra |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ping Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.